Therapeutic Approach

Archive: February, 2015

Ritter Pharmaceuticals Names Matthew W. Foehr to its Board of Directors

LOS ANGELES (February 9, 2015) – Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company focused on gastrointestinal disorders, announces the appointment of Matthew W. Foehr to the Company’s Board of Directors. Mr. Foehr is President and Chief Operating Officer of Ligand Pharmaceuticals (NASDAQ: LGND) and his appointment expands Ritter’s Board membership to 5 Directors. “We […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD